Source Post
Carl Kawaja: The $1B AIDS Cure Everyone Missed
Aug 21, 2025
The creator recounts a past investment in a small Quebec-based company that was developing an AIDS treatment. He initially traded in and out of the stock for small profits but later realized the company was acquired by GlaxoSmithKline for around $1 billion after developing a protease inhibitor, representing a significant missed opportunity.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.